Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
1.110
-0.020 (-1.77%)
Feb 23, 2026, 4:00 PM EST - Market closed
Standard BioTools Revenue
Standard BioTools had revenue of $19.55M in the quarter ending September 30, 2025, a decrease of -11.47%. This brings the company's revenue in the last twelve months to $128.83M, up 8.89% year-over-year. In the year 2024, Standard BioTools had annual revenue of $174.43M with 64.03% growth.
Revenue (ttm)
$128.83M
Revenue Growth
+8.89%
P/S Ratio
2.51
Revenue / Employee
$207,502
Employees
818
Market Cap
426.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 174.43M | 68.09M | 64.03% |
| Dec 31, 2023 | 106.34M | 8.39M | 8.57% |
| Dec 31, 2022 | 97.95M | -32.63M | -24.99% |
| Dec 31, 2021 | 130.58M | -7.56M | -5.47% |
| Dec 31, 2020 | 138.14M | 20.90M | 17.83% |
| Dec 31, 2019 | 117.24M | 4.28M | 3.79% |
| Dec 31, 2018 | 112.96M | 11.03M | 10.82% |
| Dec 31, 2017 | 101.94M | -2.51M | -2.40% |
| Dec 31, 2016 | 104.45M | -10.27M | -8.95% |
| Dec 31, 2015 | 114.71M | -1.74M | -1.50% |
| Dec 31, 2014 | 116.46M | 45.27M | 63.60% |
| Dec 31, 2013 | 71.18M | 18.85M | 36.02% |
| Dec 31, 2012 | 52.33M | 9.47M | 22.09% |
| Dec 31, 2011 | 42.87M | 9.31M | 27.73% |
| Dec 31, 2010 | 33.56M | 8.15M | 32.06% |
| Dec 31, 2009 | 25.41M | 10.07M | 65.58% |
| Dec 27, 2008 | 15.35M | 8.07M | 110.96% |
| Dec 29, 2007 | 7.28M | 877.00K | 13.71% |
| Dec 31, 2006 | 6.40M | -1.28M | -16.63% |
| Dec 31, 2005 | 7.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 818.06M |
| OrthoPediatrics | 227.41M |
| Cerus | 199.19M |
| Cytek Biosciences | 196.83M |
| Pacific Biosciences of California | 160.01M |
| RxSight | 142.09M |
| NeuroPace | 94.86M |
| Delcath Systems | 79.60M |
LAB News
- 14 days ago - Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 24 days ago - Standard BioTools Completes Sale of SomaLogic to Illumina - GlobeNewsWire
- 6 weeks ago - Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue - GlobeNewsWire
- 3 months ago - Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - Business Wire
- 3 months ago - Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks - PRNewsWire
- 3 months ago - Standard BioTools Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025 - GlobeNewsWire
- 6 months ago - Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PRNewsWire